Session 2: Translating discoveries of epileptogenic mechanisms into cures

Chair: Frances Jensen, MD

Speakers: Shlomo Shinnar, MD, PhD
Asla Pitkanen, MD, PhD
Helen Scharfman, PhD
Nico Moshe, MD


Discussants: David Van Essen, PhD
Barry Connors, PhD
Rick Huganir, PhD

Epileptogenesis

- Development of an epileptic condition
- Development and extension of tissue capable of generating chronic, recurrent, spontaneous behavioral and/or electrographic seizures
- Progression after the condition is established

Seizure-induced changes in brain

"mild" "severe" Metabolic Neuronal death Subtle structural Major structural Perturbation Gliosis changes change Axonal sprouting Altered protein Altered protein synthesis with synthesis of Dendritic transient nature enduring effects reorganization **EPILEPTOGENESIS COMORBIDITIES**



Ion channel activation Post-translational changes Immediate early genes






Minutes

Days


Weeks

Transcriptional events Neuronal death inflammation Emergence of spontaneous seizures











Talk 1: Shinnar

What clear examples of epileptogenesis are there? What is temporal profile in the human?




Talk 2: Pitkanen

What animal models show this profile? How can they be used for predictive studies and therapeutic trials?




Talk 3: Scharfman

What specific mechanisms have been elucidated? What new classes of therapeutic targets have been identified?



Talk 4: Moshe/Engel


How do we detect and measure epileptogenesis in the human? What may represent novel biomarkers for use in clinical diagnosis and treatment?



Discussants

Where might basic neuroscience research contribute to the development of new diagnostic tools, treatment strategies, and biomarker development?

CROSS-TALK



Key Topics

- Detecting epileptogenesis of paramount importance
 - Application of new technologies
- Translating between experimental and human studies
- Multiple targets for therapeutic intervention along timeline
 - Disease modification
 - Antiepileptic versus antiepileptogenic therapy